EUVIMEDEUVIMED entdecken
Kohortenstudie

Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study

Mohamad Mahdi Osman iD, Omar T Sims iD, Dian J Chiang iD

Gut and Liver · 24.07.2026

DOI: 10.5009/gnl260099 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Gut and Liver, online erschienen am 24.07.2026. Verfasst von Mohamad Mahdi Osman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hepatic encephalopathyLactuloseLiver cirrhosisPropensity scoreRifaximin

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Foundation, Cleveland, OH, USA.

ORCID-Profile: Mohamad Mahdi Osman, Omar T Sims, Dian J Chiang

Zitieren

APA

Osman, M. M., Sims, O. T., & Chiang, D. J. (2026). Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study. Gut and Liver. https://doi.org/10.5009/gnl260099

Vancouver

Osman MM, Sims OT, Chiang DJ. Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study. Gut and Liver. 2026. doi:10.5009/gnl260099

BibTeX
@article{Osman2026,
  author = {Osman, Mohamad Mahdi and Sims, Omar T and Chiang, Dian J},
  title = {Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study},
  journal = {Gut and Liver},
  year = {2026},
  doi = {10.5009/gnl260099}
}
Kostenlos starten →